News

IMI-money for intelli-research
Enlarge image

FundingEUUKSwitzerland

IMI-money for intelli-research

06.12.2012 - The Innovative Medicines Initiative funds seven new projects with a total of €237m. The main focus is on drug development and data integration.

The exciting field of stem cell research and the seemingly insurmountable ranges of biodata are undergoing in-depth analyses over the next few years. The unifying context behind these projects is the mission to improve drug development. As announced on 5 December, the Innovative Medicines Alliance (IMI) will spend in total more than €237m on research topics ranging from stem cells (STEMBANCC), data integration (EMIF and eTRIKS) and ‚green’ drug development (CHEM21) to drug-target-interaction (K4DD), drug uptake into (ORBITO) and drug distribution within (COMPACT) the body.

Within STEMBANCC ten pharmaceutical companies and 23 academic institutions from 11 countries will develop 1,500 human induced pluripotent stem cell lines from about 500 patients to study diseases and test drugs for safety and efficacy. Swiss pharma Roche initiated the project, which will be coordinated by the University of Oxford (UK). Using cells isolated from patients, the scientists hope to identify the genes and mechanisms that play a role in diseases of the nervous system such as peripheral pain, migraine, autism, schizophrenia, bipolar disorders, dementiae and diabetes. Taken together, IMI now finances 37 projects with a volume of almost €800m.

It was just in June this year, that the last current IMI projects were presented. The €215m they received is only 91% of the sum the new projects of the 4th wave will get. The IMI, a joint venture of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) is Europe’s biggest public-private partnership to accelerate the development of better drugs. Currently, applicants can bid for the 8th call „Combating Antibiotic Resistance“. The calls five to seven have already been closed for submission of Expressions of Interest (EoI) and are in different stages of processing.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/imi-money-for-intelli-research.html

M&ASwitzerland

01.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Drug AssessmentPortugalFrance

18.01.2016 A Phase I clinical trial for a drug developed by Portuguese pharma company Bial has ended in disaster. One man died, five others may have irreversible neurological damage.

Capital marketsIreland

14.01.2016 Although the global biotech boom declined during the year, 2015 has set a new record for the European public biotech sector. More than 6 billion euros was poured into the sector.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS (CH)0.05 CHF25.00%
  • NEUROSEARCH A/S (DK)2.58 DKK6.61%
  • VERONA PHARMA (UK)3.50 GBP6.06%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • SAREUM HOLDINGS (UK)0.23 GBP-8.00%

TOP

  • EPIGENOMICS (D)4.62 EUR100.0%
  • TRANSGENE (F)3.24 EUR27.6%
  • VERONA PHARMA (UK)3.50 GBP22.8%

FLOP

  • BIONOR PHARMA (N)0.92 NOK-39.5%
  • PROTHENA PLC (IE)36.77 USD-37.7%
  • CELLECTIS (F)18.99 EUR-31.2%

TOP

  • KARO BIO (S)27.70 SEK3857.1%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • 4SC (D)3.42 EUR302.4%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.90 SEK-85.4%
  • BIOTEST (D)14.31 EUR-84.3%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 04.02.2016